No evidence so far of a major role of AKT1 and GSK3B in the pathogenesis of antipsychotic-induced tardive dyskinesia

Anastasia Levchenko, Natalya Vyalova, Ivan V. Pozhidaev, Anastasiia S. Boiko, Diana Z. Osmanova, Olga Yu Fedorenko, Arkadiy V. Semke, Nikolay A. Bokhan, Bob Wilffert, Anton J.M. Loonen, Svetlana A. Ivanova

Research output: Contribution to journalArticle

Abstract

Objective: AKT1 and GSK3B take part in one of the intracellular cascades activated by the D2 dopamine receptor (DRD2). This receptor is antagonized by antipsychotics and plays a role in the pathogenesis of antipsychotic-induced tardive dyskinesia (TD). The present study investigated association of several polymorphisms in the two candidate genes, AKT1 and GSK3B, with TD in antipsychotic-treated patients with schizophrenia. Methods: DNA samples from 449 patients from several Siberian regions (Russia) were genotyped, and the results were analyzed using chi-squared tests and analyses of variance. Results: Antipsychotic-induced TD was not associated with either of the tested functional polymorphisms (rs334558, rs1130214, and rs3730358). Conclusions: Despite regulation of AKT1 and GSK3B by DRD2, we found no evidence that these two kinases play a major role in the pathogenesis of antipsychotic-induced TD. These results agree with previously published data and necessitate further exploration of other pathogenic mechanisms, such as neurotoxicity due to excessive dopamine metabolism.

Original languageEnglish
Article numbere2685
JournalHuman Psychopharmacology
Volume34
Issue number1
DOIs
Publication statusPublished - 1 Jan 2019

Fingerprint

Antipsychotic Agents
Dopamine D2 Receptors
Russia
Dopamine
Schizophrenia
Analysis of Variance
Phosphotransferases
Tardive Dyskinesia
DNA
Genes

Keywords

  • AKT1
  • antipsychotics
  • GSK3B
  • pharmacogenetics
  • schizophrenia
  • tardive dyskinesia

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

No evidence so far of a major role of AKT1 and GSK3B in the pathogenesis of antipsychotic-induced tardive dyskinesia. / Levchenko, Anastasia; Vyalova, Natalya; Pozhidaev, Ivan V.; Boiko, Anastasiia S.; Osmanova, Diana Z.; Fedorenko, Olga Yu; Semke, Arkadiy V.; Bokhan, Nikolay A.; Wilffert, Bob; Loonen, Anton J.M.; Ivanova, Svetlana A.

In: Human Psychopharmacology, Vol. 34, No. 1, e2685, 01.01.2019.

Research output: Contribution to journalArticle

Levchenko, A, Vyalova, N, Pozhidaev, IV, Boiko, AS, Osmanova, DZ, Fedorenko, OY, Semke, AV, Bokhan, NA, Wilffert, B, Loonen, AJM & Ivanova, SA 2019, 'No evidence so far of a major role of AKT1 and GSK3B in the pathogenesis of antipsychotic-induced tardive dyskinesia', Human Psychopharmacology, vol. 34, no. 1, e2685. https://doi.org/10.1002/hup.2685
Levchenko, Anastasia ; Vyalova, Natalya ; Pozhidaev, Ivan V. ; Boiko, Anastasiia S. ; Osmanova, Diana Z. ; Fedorenko, Olga Yu ; Semke, Arkadiy V. ; Bokhan, Nikolay A. ; Wilffert, Bob ; Loonen, Anton J.M. ; Ivanova, Svetlana A. / No evidence so far of a major role of AKT1 and GSK3B in the pathogenesis of antipsychotic-induced tardive dyskinesia. In: Human Psychopharmacology. 2019 ; Vol. 34, No. 1.
@article{75c22dbc7e3c41589051081ffe89d866,
title = "No evidence so far of a major role of AKT1 and GSK3B in the pathogenesis of antipsychotic-induced tardive dyskinesia",
abstract = "Objective: AKT1 and GSK3B take part in one of the intracellular cascades activated by the D2 dopamine receptor (DRD2). This receptor is antagonized by antipsychotics and plays a role in the pathogenesis of antipsychotic-induced tardive dyskinesia (TD). The present study investigated association of several polymorphisms in the two candidate genes, AKT1 and GSK3B, with TD in antipsychotic-treated patients with schizophrenia. Methods: DNA samples from 449 patients from several Siberian regions (Russia) were genotyped, and the results were analyzed using chi-squared tests and analyses of variance. Results: Antipsychotic-induced TD was not associated with either of the tested functional polymorphisms (rs334558, rs1130214, and rs3730358). Conclusions: Despite regulation of AKT1 and GSK3B by DRD2, we found no evidence that these two kinases play a major role in the pathogenesis of antipsychotic-induced TD. These results agree with previously published data and necessitate further exploration of other pathogenic mechanisms, such as neurotoxicity due to excessive dopamine metabolism.",
keywords = "AKT1, antipsychotics, GSK3B, pharmacogenetics, schizophrenia, tardive dyskinesia",
author = "Anastasia Levchenko and Natalya Vyalova and Pozhidaev, {Ivan V.} and Boiko, {Anastasiia S.} and Osmanova, {Diana Z.} and Fedorenko, {Olga Yu} and Semke, {Arkadiy V.} and Bokhan, {Nikolay A.} and Bob Wilffert and Loonen, {Anton J.M.} and Ivanova, {Svetlana A.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/hup.2685",
language = "English",
volume = "34",
journal = "Human Psychopharmacology",
issn = "0885-6222",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - No evidence so far of a major role of AKT1 and GSK3B in the pathogenesis of antipsychotic-induced tardive dyskinesia

AU - Levchenko, Anastasia

AU - Vyalova, Natalya

AU - Pozhidaev, Ivan V.

AU - Boiko, Anastasiia S.

AU - Osmanova, Diana Z.

AU - Fedorenko, Olga Yu

AU - Semke, Arkadiy V.

AU - Bokhan, Nikolay A.

AU - Wilffert, Bob

AU - Loonen, Anton J.M.

AU - Ivanova, Svetlana A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: AKT1 and GSK3B take part in one of the intracellular cascades activated by the D2 dopamine receptor (DRD2). This receptor is antagonized by antipsychotics and plays a role in the pathogenesis of antipsychotic-induced tardive dyskinesia (TD). The present study investigated association of several polymorphisms in the two candidate genes, AKT1 and GSK3B, with TD in antipsychotic-treated patients with schizophrenia. Methods: DNA samples from 449 patients from several Siberian regions (Russia) were genotyped, and the results were analyzed using chi-squared tests and analyses of variance. Results: Antipsychotic-induced TD was not associated with either of the tested functional polymorphisms (rs334558, rs1130214, and rs3730358). Conclusions: Despite regulation of AKT1 and GSK3B by DRD2, we found no evidence that these two kinases play a major role in the pathogenesis of antipsychotic-induced TD. These results agree with previously published data and necessitate further exploration of other pathogenic mechanisms, such as neurotoxicity due to excessive dopamine metabolism.

AB - Objective: AKT1 and GSK3B take part in one of the intracellular cascades activated by the D2 dopamine receptor (DRD2). This receptor is antagonized by antipsychotics and plays a role in the pathogenesis of antipsychotic-induced tardive dyskinesia (TD). The present study investigated association of several polymorphisms in the two candidate genes, AKT1 and GSK3B, with TD in antipsychotic-treated patients with schizophrenia. Methods: DNA samples from 449 patients from several Siberian regions (Russia) were genotyped, and the results were analyzed using chi-squared tests and analyses of variance. Results: Antipsychotic-induced TD was not associated with either of the tested functional polymorphisms (rs334558, rs1130214, and rs3730358). Conclusions: Despite regulation of AKT1 and GSK3B by DRD2, we found no evidence that these two kinases play a major role in the pathogenesis of antipsychotic-induced TD. These results agree with previously published data and necessitate further exploration of other pathogenic mechanisms, such as neurotoxicity due to excessive dopamine metabolism.

KW - AKT1

KW - antipsychotics

KW - GSK3B

KW - pharmacogenetics

KW - schizophrenia

KW - tardive dyskinesia

UR - http://www.scopus.com/inward/record.url?scp=85059702937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059702937&partnerID=8YFLogxK

U2 - 10.1002/hup.2685

DO - 10.1002/hup.2685

M3 - Article

VL - 34

JO - Human Psychopharmacology

JF - Human Psychopharmacology

SN - 0885-6222

IS - 1

M1 - e2685

ER -